SURMOUNT-5: Zepbound superior to Wegovy in head-to-head trial showing an average weight loss of 20.2% vs. 13.7%
top of page
Browse by category
Search
Eli Lilly and Company has announced topline results from the SURMOUNT-5 phase 3b open-label randomised clinical trial that found Zepbound...
Adults with pre-diabetes and obesity or overweight treated with tirzepatide had sustained weight loss and nearly 99% remained diabetes-free at 176 weeks
Results from the Phase 3 SURMOUNT-1 three-year study (176-week treatment period), the longest completed study to date of tirzepatide,...
Palatin completes study enrolment of bremelanotide plus tirzepatide to treat obesity
Palatin Technologies has completed enrolment in the study entitled "BMT-801, A Phase II, Randomized, Double-Blind, Placebo-Controlled,...
Tirzepatide results in greater weight loss in women than men
All doses of tirzepatide consistently reduced body weight in women and men, but women experienced greater weight loss, according to post...
Large-scale population analysis confirms safety profile of tirzepatide
An analysis of real-world evidence from the FDA Adverse Event Reporting System (FAERS) database of tirzepatide, presented at this year's...
Journal Watch 10/7/2024
Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...
Patients receiving tirzepatide were significantly more likely to achieve clinically meaningful weight loss compared with those treated receiving semaglutide
Individuals with overweight or obesity treated with tirzepatide were significantly more likely to achieve clinically meaningful weight...
Tirzepatide associated with a potential targeted effect on visceral fat and liver fat
Exploratory analysis from the SURPASS-3 MRI study has shown a significant reduction of both visceral- and liver fat z-scores, and a shift...
Semaglutide and tirzepatide decrease cravings and reduce alcohol consumption
An analysis of social media posts and a remote study of individuals with obesity who reported using semaglutide and tirzepatide, has...
Journal Watch 01/11/2023
Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...
Browse by tag
bottom of page